LOS ANGELES, CA--(Marketwired - Aug 23, 2016) - Decision Diagnostics Corp. (OTC PINK: DECN), the manufacturer, quality plan administrator and the exclusive worldwide sales, service and regulatory processes agent for GenStrip™ 50 and the GenUltimate!™ glucose test strips, both designed to work with the market leading Johnson & Johnson's ("J&J") LifeScan OneTouch Ultra family of glucose testing meters, and the in-development GenSure!™ and GenChoice!™ glucose test strips targeted to the U.S. and/or developing world markets today conveys positive results from the execution of the marketing plan for the "Gen" family of glucose testing products.
Intrinsic to the attainment of the company's identified revenue goals was the attainment of a series of successfully executed tactics running both concurrently and, in some instances, consecutively. The central and initial hurdle was the complete defeat of J&J in its efforts to exclude our participation in a free and fair competitive marketplace. During the product market hiatus driven by that litigation, the company utilized the time and opportunity to prepare for a re-launch of Genstrip 50 while simultaneously developing a suite of new market additions, both in and out of the blood glucose test strip market segment. Those new line additions include GenUltimate!, currently sold in ever more market niches and other unique line expansions that will be formally introduced beginning with the fourth quarter of 2016.
Keith Berman, PEO and CFO of DECN, commented, "As relayed in prior communications, Decision Diagnostics and Pharma Tech engaged the lengthy J&J/Lifescan litigation battles solely to regain the right to legally sell the Genstrip 50 and its derivative products without restraint or intimidation. Now that those legal conflicts have been concluded with prejudice via the Federal courts as of May 20, 2016, we have enthusiastically begun implementing the marketing plan for our 'Gen' products. The first target in our post-litigation market strategy entailed the capture of new on-line retailer agreements and in some instances the re-capture of agreements we were forced to delay."
The company has been aggressively pursuing the on-line retailer market and, as a result of those efforts, the company's products can be immediately purchased at a multitude of on-line retailer locations including:
Mr. Berman concluded, "The Company lost considerable time and resources defending itself from the baseless legal attacks by J&J/Lifescan. It is liberating to now redirect our corporate focus on our primary tasks as a responsible business; selling our products, attaining earnings and driving share price. Our stockholders can anticipate several like communications regarding advances in this space with some of the largest global mass merchandisers, including one just signed as this release was written. It is gratifying to finally be able to take the consequential step of concluding agreements to offer our 'Gen' products through these major on-line portals. Implicit in the fulfillment of our marketing plan through these on-line retailers is a formal declaration of the company's reemergence and, we hope, the first of many like communications that document market share progression."
This release contains the Company's forward-looking statements which are based on management's current expectations and assumptions as of August 22, 2016, regarding the Company's business and performance, its prospects, current factors, the economy and other future conditions and forecasts of future events, circumstances and results.